|
1) |
Stephan C, Jung K, Cammann H, et al. An aritificial neural network considerably improves the diagnostic power of percent prostate-specific antigen in prostate cancer diagnosis:results of a 5-year investigation. Int J Cancer. 2002;99(3):466-73. |
2) |
Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am. 2003;30(4):677-86. |
3) |
Oberpenning F, Weining C, Brandt B, et al. Combining free and total prostate specific antigen assays from different manufacturers:the pitfalls. Eur Urol. 2002;42(6):577-82;discussion 582. |
4) |
Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002;167(5):2017-23;discussion 2023-4. |
5) |
Ellison L, Cheli CD, Bright S, et al. Cost-benefit analysis of total, free/total, and complexed prostate specific antigen for prostate cancer screening. Urology. 2002;60(4 Suppl 1):42-6. |
6) |
Saika T, Tsushima T, Nasu Y, et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer. 2002 15;94(6):1685-91. |